Skip to content

Measurement of the Energy Metabolism of Peritoneal Dialysis Patients

Study in Calorimetric Room of the Energy Metabolism of Renal Impairment Patients Treated With Automated Peritoneal Dialysis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03347305
Acronym
CALIMERO 2
Enrollment
24
Registered
2017-11-20
Start date
2016-08-01
Completion date
2019-12-31
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure

Keywords

Energy expenditure, Peritoneal dialysis

Brief summary

The daily energy expenditure of patients treated with peritoneal dialysis could be increased compared to the general population and promote the development of a state of undernutrition. Conversely, the absorption of glucose by transperitoneal route could contribute to the occurrence of a metabolic syndrome. The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber.

Detailed description

The daily energy expenditure of patients treated with peritoneal dialysis could be increased compared to the general population and promote the development of a state of undernutrition. Conversely, the absorption of glucose by transperitoneal route could contribute to the occurrence of a metabolic syndrome. The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber.

Interventions

BEHAVIORALautomated DP

Energy expenditure measurement

The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber

Sponsors

Pôle Santé République
CollaboratorOTHER
Service de Néphrologie et Hémodialyse
CollaboratorUNKNOWN
Jacques Lacarin Hospital Center
CollaboratorOTHER
University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

No masking

Eligibility

Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients Group DPA * Male patients * Aged 18 to 70 years * With end-stage renal disease * Treated by automatic peritoneal * Social security cover * Without acute events in the 3 months prior to inclusion * PCR \< 30 mg/L * Written informed consent * Baecke activity score from 5 to 10 Healthy Volunteers * Male patients * Aged 18 to 70 years * Patients matched by lean body mass (± 2 kgs) and age (± 5 years) * Having a glomerular filtration rate estimated with the formula CKD-EPI creatinine \> 60 mL / min / 1.73 m 2 * PCR \< 3 mg/L * Social security cover * Written informed consent * Baecke activity score from 5 to 10

Exclusion criteria

* • - Female * Type 1 or 2 diabetes requiring a antidiabetic treatment * Decompensated heart failure * Smoking more than 5 cigarettes a day * Alcoholic patients, drinking more than 3 glass of alcohol a day * Patient Corticotherapy in progress * Patient with evolutive acute pathology * Person who has participated in another study within the last 30 days or is in period of exclusion on the National File of Healthy Volunteers

Design outcomes

Primary

MeasureTime frameDescription
Energy expenditure measured by indirect calorimetry in a calorimetric chamberat day 1Energy expenditure measured by indirect calorimetry in a calorimetric chamber

Secondary

MeasureTime frameDescription
respiratory quotient (RQ)at day1Nature of the oxidized nutrients determined from the measurement of the respiratory quotient
Actimetryat day 1Estimated ambulatory energy expenditure from heart rate
HGPOat day 1Charges of blood insulin concentration, and glucose in response to oral glucose load

Countries

France

Contacts

Primary ContactPatrick LACARIN
placarin@chu-clermontferrand.fr0473751195

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026